Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours.

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours.

Item
http://www.wikidata.org/entity/Q36977529
Elevated levels of plasma angiogenic factors are associated with human lymphatic filarial infectionsPhase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancerMultitarget inhibitors derived from crosstalk mechanism involving VEGFR2.Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma.Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).Tumor vasculature as target for therapeutic intervention.Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies.Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics.Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivoPhase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors.
P2860

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours.

Item
http://www.wikidata.org/entity/Q36977529
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Phase I dose escalation study ...... s with advanced solid tumours.
@en
type
label
Phase I dose escalation study ...... s with advanced solid tumours.
@en
prefLabel
Phase I dose escalation study ...... s with advanced solid tumours.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P6179
P698
P932
P356
P1433
P1476
Phase I dose escalation study ...... s with advanced solid tumours.
@en
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P6179
P698
P932